AntriaBio is focused on developing innovative therapies for rare diseases, particularly hyperinsulinism, which can lead to dangerously low blood sugar levels in patients of all ages. Their lead product, RZ358 (ersodetug), is currently undergoing a Phase 3 clinical trial aimed at treating congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI). The company has reported promising results from earlier studies, indicating that RZ358 can significantly reduce hypoglycemic events, with improvements of up to 90% observed in some patients. This investigational therapy is designed to address the underlying causes of excessive insulin production, thereby restoring balance to the lives of those affected by this condition.

In addition to their work on hyperinsulinism, AntriaBio is also developing RZ402, an oral small molecule designed to treat Diabetic Macular Edema (DME), a serious complication of diabetes that threatens vision. RZ402 functions as a selective plasma kallikrein inhibitor, aiming to reduce vascular leakage and inflammation associated with DME. Early Phase 2 results have shown that RZ402 can significantly decrease central subfield thickness in the retina, suggesting its potential effectiveness in managing this condition. AntriaBio's commitment to patient-centered care drives their research and development efforts, as they strive to provide transformative solutions for patients facing serious unmet medical needs.

United States

Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. 

For more information, visit: www.rezolutebio.com.

Rezolute, Inc.

Company Details